Skip to main content
Caplight Logo









Harbinger Health

Harbinger Health

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://harbinger-health.com/

Last Round

Series B

Extension

Apr 14, 2026

Total Funding Raised

$290M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Harbinger Health is a biotechnology company that develops AI-enabled, blood-based multi-cancer detection tests designed to identify cancer at its earliest stages.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

multi-cancer detectionMCEDliquid biopsycfDNA methylationearly cancer detectioncancer screeningdiagnostic platformoncology diagnosticsblood-based testclinical diagnosticsbiotech startupprecision oncologycancer biomarkerclinical validation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Harbinger Health Comparables

Compare Harbinger Health with similar companies based on industry and business-model similarity.

Harbinger Health comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Adela
89%
ClearNote Health
86%
Delfi Diagnostics
82%

Harbinger Health Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionApr 14, 2026
Series BSep 28, 2023
Series ADec 7, 2021

Harbinger Health Investors

Notable investors and investment history

Harbinger Health investors
InvestorRounds
Pictet GroupSeries B Extension, Series B
M&G InvestmentsSeries B Extension, Series B
Partners InvestmentSeries B Extension, Series B
Flagship PioneeringSeries B Extension, Series A, Series B
M&G plcSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 58% MoM, reaching 4.4K.

  • Apr 17, 2026

    Models infer lung cancer progression from blood draw cfDNA methylation data.

Harbinger Health Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Harbinger Health Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Harbinger Health's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range65
Year Founded2020
Last FundingApr 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?